Bulk Pharmaceutical API Sources for GLYCINE 1.5% IN PLASTIC CONTAINER

Bulk Pharmaceutical API Sources for GLYCINE 1.5% IN PLASTIC CONTAINER

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		sJX`BDdvu@@
Specs		AB-131/40217813
Sigma-Aldrich		410225_SIAL

Global Bulk API Sourcing for Glycine 1.5% in Plastic Container

Last updated: February 19, 2026

This report analyzes the global market for bulk Active Pharmaceutical Ingredient (API) sources for Glycine 1.5% in plastic containers. The focus is on identifying key manufacturers, regional production capabilities, regulatory compliance, and market trends influencing supply chain stability and cost. Glycine is a simple amino acid used in various pharmaceutical formulations, including intravenous solutions and buffer systems. The specific presentation of a 1.5% concentration in a plastic container implies use in specific therapeutic areas or diagnostic applications.

What is the Global Production Landscape for Glycine API?

The global production of Glycine API is characterized by a concentration of manufacturing in Asia, particularly China and India, due to cost advantages and established chemical synthesis infrastructure. However, manufacturers in Europe and North America also contribute, often focusing on higher-purity grades and specialized applications.

Key Glycine API Manufacturers

A significant portion of global Glycine API production is managed by a limited number of entities. These manufacturers vary in scale, product purity, and regulatory certifications.

• China: Dominated by a large number of chemical manufacturers, many of which produce pharmaceutical-grade Glycine. Key players include:
  • Hubei Xingfa Chemicals Group Co., Ltd.
  • Shandong Dongfeng Chemical Co., Ltd.
  • Hebei Chengxin Co., Ltd.
• India: A growing hub for API production, with several companies supplying Glycine for pharmaceutical use. Notable manufacturers include:
  • Annamalai Chemicals Ltd.
  • Tata Chemicals Ltd.
• Europe: European manufacturers often adhere to stringent Good Manufacturing Practices (GMP) and focus on high-value markets.
  • Evonik Industries AG (Germany)
  • Ajinomoto (Euro-API)
• North America: While not the largest production base, some North American companies are involved in specialized Glycine derivatives or high-purity grades.
  • Merck KGaA (operates globally, with North American presence)

Production Capacities and Scale

Production capacities vary significantly. Large Chinese manufacturers can produce thousands of metric tons annually, catering to the broad demand for Glycine. European and North American producers often operate at smaller scales, emphasizing niche markets or meeting specific pharmacopoeial standards for highly regulated markets. The API for Glycine 1.5% in plastic containers requires specific particle size distribution and impurity profiles, which can influence the selection of manufacturers.

What are the Regulatory Requirements for Glycine API in Pharmaceutical Applications?

Sourcing Glycine API for pharmaceutical use necessitates adherence to strict regulatory standards to ensure patient safety and product efficacy. These standards are governed by major pharmacopoeias and regulatory agencies worldwide.

Pharmacopoeial Standards

Glycine API must comply with relevant pharmacopoeial monographs. Key pharmacopoeias include:

• United States Pharmacopeia (USP): Specifies purity, identification, assay limits, and impurity thresholds. The USP monograph for Glycine sets limits for related substances, heavy metals, and other contaminants.
• European Pharmacopoeia (Ph. Eur.): Similar to USP, it defines acceptance criteria for Glycine intended for pharmaceutical use.
• Japanese Pharmacopoeia (JP): Another critical standard, especially for products intended for the Japanese market.

Compliance with these monographs is a prerequisite for market entry in their respective regions.

Good Manufacturing Practices (GMP)

Manufacturers of pharmaceutical-grade Glycine API must operate under current Good Manufacturing Practices (cGMP). This involves:

• Quality Management Systems: Robust systems for process control, batch record keeping, and change control.
• Facility and Equipment Qualification: Ensuring that manufacturing facilities and equipment are validated and maintained.
• Personnel Training: Qualified personnel are essential for consistent production.
• Analytical Testing: Rigorous in-process and final product testing against pharmacopoeial and internal specifications.

Regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) conduct inspections to verify GMP compliance.

DMF and CEP Filings

For pharmaceutical applications, manufacturers often file Drug Master Files (DMFs) with regulatory bodies such as the FDA, or obtain Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs) from the European Directorate for the Quality of Medicines & HealthCare (EDQM). These filings provide confidential detailed information about the manufacturing process, quality control, and stability of the API.

• DMFs: Allow regulatory agencies to review the API manufacturing information without disclosing proprietary data to the drug product manufacturer.
• CEPs: Provide a standardized way for manufacturers to demonstrate compliance with Ph. Eur. requirements, facilitating registration of pharmaceutical products in Europe and other regions that recognize CEPs.

What are the Supply Chain Considerations for Glycine API in Plastic Containers?

The supply chain for Glycine API intended for use in plastic containers involves specific considerations beyond API sourcing, including the container material, sterilization, and logistics.

API Specifications for 1.5% Solution

The Glycine API must meet specific criteria for dissolution and purity to form a stable 1.5% aqueous solution suitable for parenteral or other administration. This includes:

• Particle Size Distribution: Affects dissolution rate. Manufacturers need to control this parameter.
• Impurity Profile: Trace impurities can affect solution stability, color, and safety. Specific limits for potential leachables from plastic containers may also be relevant.
• Microbiological Purity: For sterile applications, the API may need to meet specific endotoxin and microbial limits, or be processed in a sterile manner.

Plastic Container Manufacturing and Compatibility

The use of plastic containers introduces additional supply chain complexity.

• Container Material: Common plastics for pharmaceutical solutions include Polyethylene (PE), Polypropylene (PP), and Polyvinyl Chloride (PVC). The choice of polymer depends on chemical compatibility with Glycine solution, sterilization method, and required physical properties.
• Leachables and Extractables: Rigorous testing is required to ensure that no harmful substances leach from the plastic into the Glycine solution over its shelf life. This is a critical regulatory hurdle.
• Sterilization Methods: Plastic containers are typically sterilized using methods like ethylene oxide (EtO) or gamma irradiation. The API must be stable under these conditions, or the solution must be terminally sterilized after filling.
• Container Suppliers: Pharmaceutical companies source plastic containers from specialized suppliers who also adhere to stringent quality and regulatory standards (e.g., ISO 13485, cGMP). Examples include:
  • Gerresheimer
  • BD Medical
  • Schott Pharma (though historically glass, they offer plastic solutions)

Logistics and Storage

• Temperature Control: Glycine solutions generally require controlled room temperature storage, but specific temperature ranges must be maintained throughout the supply chain.
• Packaging Integrity: Protection against damage and contamination during transit is paramount.
• Lead Times: Sourcing both API and compatible sterile plastic containers requires significant lead times, necessitating robust demand forecasting and inventory management.

What are the Market Trends and Cost Drivers for Glycine API?

Several factors influence the market dynamics, pricing, and availability of Glycine API.

Demand Drivers

• Intravenous Solutions: Glycine is a component of some IV solutions used for hydration, nutrition, and as a diluent.
• Ophthalmic Solutions: Used in irrigating solutions for ocular surgery.
• Diagnostic Agents: Employed in certain diagnostic procedures.
• Buffer Systems: Used in various biochemical and pharmaceutical processes.

The demand for Glycine 1.5% in plastic containers is driven by specific therapeutic applications, which can be niche but critical.

Cost Drivers

• Raw Material Costs: The primary feedstock for Glycine production is chloroacetic acid and ammonia. Fluctuations in these commodity chemical prices directly impact Glycine API costs.
• Energy Costs: Chemical synthesis is energy-intensive. Rising global energy prices increase manufacturing costs.
• Regulatory Compliance: Meeting cGMP standards, obtaining pharmacopoeial certifications, and maintaining DMFs or CEPs adds significant overhead. Costs associated with audits, validation, and quality control are substantial.
• Labor Costs: While Asia offers lower labor costs, rising wages in established manufacturing regions still influence pricing.
• Environmental Regulations: Stricter environmental regulations on chemical manufacturing in China and other regions can lead to increased compliance costs and potential supply disruptions.
• Geopolitical Factors: Trade policies, tariffs, and geopolitical instability can impact the cost and availability of raw materials and finished APIs.
• Container and Packaging Costs: The cost of high-quality, sterile plastic containers, including their sterilization and validation, is a significant component of the final product cost.

Market Trends

• Supply Chain Resilience: Increasing emphasis on diversifying sourcing away from single regions to mitigate risks associated with geopolitical events, pandemics, or natural disasters.
• Quality and Traceability: Growing demand for APIs with fully traceable supply chains and robust quality assurance documentation.
• Sustainability: Pressure on manufacturers to adopt more environmentally friendly production processes.
• Technological Advancements: Innovations in chemical synthesis and purification can lead to more efficient and cost-effective production, or enable higher purity grades.

Key Takeaways

• Asia Dominates Production: China and India are primary sources of bulk Glycine API, with substantial production capacities.
• Regulatory Rigor: Compliance with USP, Ph. Eur., JP, and cGMP standards is non-negotiable for pharmaceutical applications. DMFs and CEPs are critical for market access.
• Plastic Container Integration: Sourcing Glycine API for plastic containers requires compatibility testing, consideration of leachables/extractables, and sterile manufacturing capabilities from both API and container suppliers.
• Cost Volatility: Raw material prices, energy costs, and stringent regulatory requirements are significant cost drivers.
• Supply Chain Diversification: Global events are prompting a strategic shift towards more resilient and diversified API sourcing.

Frequently Asked Questions

1. What are the primary risks associated with sourcing Glycine API from China or India for European or North American markets? Risks include potential quality variations, longer lead times due to shipping and customs, and evolving regulatory landscapes. Geopolitical tensions and intellectual property concerns can also be factors.

2. How does the specification for Glycine API for parenteral use differ from that for other applications? Parenteral grade Glycine API must meet stringent requirements for sterility, endotoxin levels, and extremely low levels of specific impurities, as well as possess a controlled particle size for dissolution.

3. What is the typical shelf life of Glycine API, and how does this impact inventory management? Glycine API typically has a shelf life of 2-5 years when stored under controlled conditions, allowing for moderate inventory levels. However, the stability of the formulated product in its plastic container is also a critical factor.

4. Are there specific certifications beyond cGMP and pharmacopoeial compliance that are advisable for Glycine API suppliers? Certifications such as ISO 9001 (Quality Management Systems) demonstrate a broader commitment to quality. For suppliers of finished dosage forms or APIs for sterile products, ISO 13485 (Medical Devices) for container components can be relevant, though not directly for the API itself.

5. What impact do the sterilization methods for plastic containers have on the selection of Glycine API? The API must be stable to gamma irradiation or ethylene oxide sterilization if terminal sterilization of the filled container is planned. Alternatively, if the API is to be filtered and filled into pre-sterilized containers under aseptic conditions, then the API's intrinsic microbiological purity becomes more critical.

Citations

[1] United States Pharmacopeial Convention. (n.d.). United States Pharmacopeia (USP). Retrieved from uspharmacopeia.org

[2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia (Ph. Eur.). Retrieved from edqm.eu

[3] Japanese Pharmacopoeial Convention. (n.d.). Japanese Pharmacopoeia (JP). Retrieved from jp.pharm.or.jp

[4] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from fda.gov

[5] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from ema.europa.eu